Mahindra Manulife Mutual Fund trimmed its stake in Neuland Laboratories from 1.93% to 1.52%, selling 51,606 shares.
A pharmaceutical manufacturer engaged in the production and distribution of bulk drugs, Neuland Labs serves both domestic and international markets through its integrated operations. The company specializes in manufacturing active pharmaceutical ingredients and provides contract manufacturing services to global pharmaceutical companies. Its facilities are designed to meet stringent international quality and regulatory standards for pharmaceutical production.
Joint venture between Mahindra Group and Manulife Investment Management of Canada. Manages over Rs 30,000 crore. Focuses on equity and hybrid fund strategies with a quality growth bias inherited from the Manulife global investment framework. Leverages the Mahindra Group's brand and distribution reach for retail investor outreach.
